ReviewExpert reviews in molecular medicine2023
Review in Expert reviews in molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Article
- The Role of Selected Bacteria in Breast Cancer Initiation and Development.International journal of molecular sciences · 2026Review
- Gastric bacterial microbiota and gastric carcinogenesis: from dysbiosis to immune remodeling and therapeutic opportunities.Frontiers in immunology · 2026Review
- Microbiome-Driven Mechanisms in Breast Cancer: Emerging Evidence From Gut Microbial Signatures to Therapeutic Response.BioMed research international · 2026Review
- cRGD-Targeted Nanoparticles Co-Loaded with Ag, Quercetin and PD-L1 siRNA with Combined Antibacterial and Immunotherapeutic Functions AgainstInternational journal of nanomedicine · 2026Article
- Microbial Signatures in Breast Cancer: Exploring New Potentials Across Body Niches.International journal of molecular sciences · 2025Review
- Exploring the Microbiome in Breast Cancer: The Role ofMicroorganisms · 2025Review
- Article
- Emerging Role of Gut Microbiota in Breast Cancer Development and Its Implications in Treatment.Metabolites · 2024Review
- Leucine restriction ameliorates Fusobacterium nucleatum-driven malignant progression and radioresistance in nasopharyngeal carcinoma.Cell reports. Medicine · 2024Article
- The interplay between persistent pathogen infections with tumor microenvironment and immunotherapy in cancer.Cancer medicine · 2024Review
- Review
- Nutrition Intervention and Microbiome Modulation in the Management of Breast Cancer.Nutrients · 2024Review
- Fusobacterium nucleatum carcinogenesis and drug delivery interventions.Advanced drug delivery reviews · 2024Review
- Review
- Promising dawn in tumor microenvironment therapy: engineering oral bacteria.International journal of oral science · 2024Review
- Association between oral microbiome and seven types of cancers in East Asian population: a two-sample Mendelian randomization analysis.Frontiers in molecular biosciences · 2023Article
- Relationships among breast, gut, and oral microbiota across diverse pathological types of breast cancer, a Chinese cohort study.Frontiers in molecular biosciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer was the most commonly diagnosed cancer worldwide in 2020. Greater understanding of the factors which promote tumour progression, metastatic development and therapeutic resistance is needed. In recent years, a distinct microbiome has been detected in the breast, a site previously thought to be sterile. Here, we review the clinical and molecular relevance of the oral anaerobic bacterium
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.